Three Health Care Stocks That Could Revitalize Your Portfolio This November
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Should l Buy ACHC?
Source: Benzinga
Oversold Stocks Opportunity: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Alvotech SA Update: Alvotech's stock dropped 41% over the past month following an FDA Complete Response Letter regarding its AVT05 biosimilar application, with an RSI of 18.8 and a closing price of $5.03.
Acadia Healthcare Performance: Acadia Healthcare's stock fell 19% in the last month, with an RSI of 27.9, and it closed at $21.31 ahead of its third-quarter results announcement.
Akebia Therapeutics Decline: Akebia Therapeutics experienced a 33% drop in stock price over five days, with an RSI of 29.4, closing at $2.12 after reporting inducement grants.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACHC
Wall Street analysts forecast ACHC stock price to fall
11 Analyst Rating
5 Buy
5 Hold
1 Sell
Moderate Buy
Current: 26.890
Low
13.00
Averages
18.10
High
25.00
Current: 26.890
Low
13.00
Averages
18.10
High
25.00
About ACHC
Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services. The Company owns and operates acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs), residential treatment centers and facilities providing outpatient behavioral healthcare services to serve the behavioral healthcare and recovery needs of communities throughout the United States and Puerto Rico. Its acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. Its CTCs specialize in providing medication-assisted treatment in an outpatient setting. Its specialty treatment facilities primarily consist of residential recovery facilities. It provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Its residential treatment centers treat patients with behavioral disorders in a non-hospital setting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acadia (ACHC) Q3 2025 Earnings Call Transcript
See More
David Einhorn Emphasizes Capital Protection Amid Market Rally
- Capital Protection Priority: David Einhorn emphasized in his latest investor letter that despite the market rally driven by geopolitical optimism, capital preservation remains his top priority, warning that investors may be underestimating potential downside risks.
- Market Rebound Overview: The S&P 500 has fully erased losses incurred since the onset of the Iran war, and despite the breakdown of U.S.-Iran negotiations, investors remain optimistic about a potential deal, fueling continued market gains.
- Fund Performance Insight: Greenlight Capital reported a 6.5% return in Q1, outperforming the S&P 500's 4.4% decline, yet Einhorn noted the firm maintains relatively low gross and net exposure, reflecting caution regarding valuations and the broader macroeconomic backdrop.
- Investment Strategy Adjustments: Einhorn mentioned that Greenlight had already been operating with low exposure at the conflict's onset and added a long position in October oil futures, although this investment has only seen modest gains as the market largely expects any supply disruptions to be temporary.
See More
Acadia Healthcare to Release Q1 2026 Results and Host Conference Call
- Earnings Release Schedule: Acadia Healthcare is set to announce its Q1 2026 financial results on April 29, 2026, after market close, reflecting its ongoing growth in the behavioral healthcare sector.
- Investor Conference Call: The company will hold a conference call on April 30, 2026, at 9:00 a.m. ET, aimed at institutional investors and analysts, enhancing transparency and investor relations.
- Webcast Availability: The conference call will be broadcast live on Acadia's website under the 'Investors' section, with a replay available for 30 days, ensuring investors can access the information at their convenience.
- Company Scale and Impact: As of December 31, 2025, Acadia operates 277 behavioral healthcare facilities across the U.S. and Puerto Rico, with over 12,500 beds and serving more than 84,000 patients daily, solidifying its leadership position in the industry.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Canyon Capital Advisors Exits Acadia Healthcare Position Completely
- Complete Exit: Canyon Capital Advisors fully exited its position in Acadia Healthcare by selling 521,774 shares in Q4 2026, resulting in a decrease of approximately $12.92 million in position value, indicating a pessimistic outlook on the company's future prospects.
- Poor Stock Performance: As of Tuesday, Acadia Healthcare's shares were priced at $22.74, down 22% over the past year, significantly underperforming the S&P 500, which rose about 16%, highlighting the company's lack of competitiveness in the market.
- Complex Financial Situation: Despite a 6.1% year-over-year revenue increase to $821.5 million in Q4, the company faced a $996.2 million goodwill impairment, leading to an adjusted EBITDA drop to $608.9 million, indicating operational pressures with a net leverage of 4.0x limiting financial flexibility.
- Uncertain Market Outlook: Canyon's exit suggests a preference for clearer asset-backed recovery plays over healthcare turnaround risks, prompting long-term investors to monitor occupancy trends and liability reserve stability to gauge future market sentiment shifts.
See More
Acadia (ACHC) Q3 2025 Earnings Call Transcript
See More
David Einhorn Emphasizes Capital Protection Amid Market Rally
- Capital Protection Priority: David Einhorn emphasized in his latest investor letter that despite the market rally driven by geopolitical optimism, capital preservation remains his top priority, warning that investors may be underestimating potential downside risks.
- Market Rebound Overview: The S&P 500 has fully erased losses incurred since the onset of the Iran war, and despite the breakdown of U.S.-Iran negotiations, investors remain optimistic about a potential deal, fueling continued market gains.
- Fund Performance Insight: Greenlight Capital reported a 6.5% return in Q1, outperforming the S&P 500's 4.4% decline, yet Einhorn noted the firm maintains relatively low gross and net exposure, reflecting caution regarding valuations and the broader macroeconomic backdrop.
- Investment Strategy Adjustments: Einhorn mentioned that Greenlight had already been operating with low exposure at the conflict's onset and added a long position in October oil futures, although this investment has only seen modest gains as the market largely expects any supply disruptions to be temporary.
See More
Acadia Healthcare to Release Q1 2026 Results and Host Conference Call
- Earnings Release Schedule: Acadia Healthcare is set to announce its Q1 2026 financial results on April 29, 2026, after market close, reflecting its ongoing growth in the behavioral healthcare sector.
- Investor Conference Call: The company will hold a conference call on April 30, 2026, at 9:00 a.m. ET, aimed at institutional investors and analysts, enhancing transparency and investor relations.
- Webcast Availability: The conference call will be broadcast live on Acadia's website under the 'Investors' section, with a replay available for 30 days, ensuring investors can access the information at their convenience.
- Company Scale and Impact: As of December 31, 2025, Acadia operates 277 behavioral healthcare facilities across the U.S. and Puerto Rico, with over 12,500 beds and serving more than 84,000 patients daily, solidifying its leadership position in the industry.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Canyon Capital Advisors Exits Acadia Healthcare Position Completely
- Complete Exit: Canyon Capital Advisors fully exited its position in Acadia Healthcare by selling 521,774 shares in Q4 2026, resulting in a decrease of approximately $12.92 million in position value, indicating a pessimistic outlook on the company's future prospects.
- Poor Stock Performance: As of Tuesday, Acadia Healthcare's shares were priced at $22.74, down 22% over the past year, significantly underperforming the S&P 500, which rose about 16%, highlighting the company's lack of competitiveness in the market.
- Complex Financial Situation: Despite a 6.1% year-over-year revenue increase to $821.5 million in Q4, the company faced a $996.2 million goodwill impairment, leading to an adjusted EBITDA drop to $608.9 million, indicating operational pressures with a net leverage of 4.0x limiting financial flexibility.
- Uncertain Market Outlook: Canyon's exit suggests a preference for clearer asset-backed recovery plays over healthcare turnaround risks, prompting long-term investors to monitor occupancy trends and liability reserve stability to gauge future market sentiment shifts.
See More
